

DOI: [10.4081/ejh.2019.3022](https://doi.org/10.4081/ejh.2019.3022)

Peribiliary gland damage due to liver transplantation involves peribiliary vascular plexus and vascular endothelial growth factor

Antonio Franchitto,¹ Diletta Overi,¹ Romina Mancinelli,¹ Anna Paola Mitterhofer,²
Paolo Muisean,³ Francesca Tinti,² Ilaria Umbro,² Stefan G. Hübscher,^{4,5}
Paolo Onori,¹ Eugenio Gaudio,¹ Guido Carpino⁶

¹Department of Anatomical, Histological, Forensic Medicine and Orthopedics Sciences, Sapienza University of Rome, Italy

²Department of Translational and Precision Medicine, Sapienza University of Rome, Italy

³Liver Unit, University Hospitals Birmingham NHS Foundation Trust, UK

⁴Institute of Immunology and Immunotherapy, University of Birmingham, UK

⁵Department of Cellular Pathology, Queen Elizabeth Hospital, Birmingham, UK

⁶Department of Movement, Human and Health Sciences, Division of Health Sciences, University of Rome "Foro Italico", Italy

Correspondence: Prof. Guido Carpino, Department of Movement, Human and Health Sciences, Division of Health Sciences, University of Rome "Foro Italico", Piazza Lauro De Bosis 6, 00135 Rome, Italy. Tel./Fax: +39.06.36733.202. E-mail: guido.carpino@uniroma1.it

Key words: Stem cells; bile duct; liver transplantation; biliary tract disease; Hypoxia-Inducible Factor 1 alpha.

Supplementary Table 1. Histological evaluation of bile duct injury

	0	1	2	3
Biliary epithelial cell loss	No epithelial loss	≤50% epithelial loss	>50% epithelial loss	-
Mural stroma necrosis	No necrosis	≤25% of duct wall necrotic	25-50% of duct wall necrotic	>50% of duct wall necrotic
Intramural bleeding	No bleeding	≤50% of the bile duct wall with bleeding	>50% of the bile duct wall with bleeding	-
Inflammation	No inflammation	At least one HPF with >10 leukocytes	At least one HPF with >50 leukocytes	-
PVP damage	No injury	≤50% of vessels damaged	>50% of vessels damaged	-
Arteriolonecrosis	None	≤50% of vessels damaged	>50% of vessels damaged	-
Thrombosis	Absent	Present	-	-
Periluminal PBG damage	No injury	≤50% cell loss/detachment	>50% cell loss/detachment	-
Deep PBG damage	No injury	≤50% cell loss/detachment	>50% cell loss/detachment	-

PVP, peribiliary vascular plexus; PBG, peribiliary gland; HPF, high-powered field.

Supplementary Table 2. List of primary antibodies.

Antibody	Company	Species	Code	Dilution
CD31	Dako, Glostrup, Denmark	Mouse monoclonal	M0823	1:100
Cytokeratin 7	Dako, Glostrup, Denmark	Mouse monoclonal	M7018	1:50
HIF- α	Abcam, Cambridge, UK	Mouse monoclonal	ab8366	1:50
PCNA	Dako, Glostrup, Denmark	Mouse monoclonal	M0879	1:100
SOX9	Millipore, Burlington, MA, USA	Rabbit polyclonal	AB5535	1:200
VEGF-A	Santa Cruz Biotechnology, Inc., Dallas, TX, USA	Mouse monoclonal	sc-53462	1:100
VEGFR-2	Santa Cruz Biotechnology, Inc., Dallas, TX, USA	Mouse monoclonal	sc-6251	1:50

HIF- α , Hypoxia Inducible Factor- α ; PCNA, proliferating cell nuclear antigen; SOX9, sex-determining region Y-box 9; VEGF-A, Vascular Endothelial Growth Factor-A; VEGFR-2, VEGF Receptor-2.